10 November 2023

Physiomics plc

("Physiomics" or "the Company")

Business Update

Physiomics plc (AIM: PYC), is pleased to announce that, following today's announcement of a significant grant award from Innovate UK and The Office for Life Sciences to support the Company's personalised dosing programme, Dr Jim Millen and Dr Pete Sargent will provide a business update via Investor Meet Company on 17 November 2023 at 1:00 pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 am GMT the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Physiomicsplc via:

https://www.investormeetcompany.com/physiomics-plc/register-investor.  Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PK/PD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.